EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp.) is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company has developed 3 FDA-approved sustained-release treatments in ophthalmology. In addition, DEXYCU (dexamethasone intraocular suspension) 9% was approved by U.S. Food and Drug Administration (FDA) on February 9, 2018. ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg, a micro-insert licensed to Alimera Sciences, is currently sold directly in the U.S. and several EU countries. Retisert® (ﬂuocinolone acetonide intravitreal implant) 0.59 mg, an implant, is licensed to and sold by Bausch & Lomb.
The New Drug Application (NDA) for our lead product candidate, DurasertTM (fluocinolone acetonide intravitreal implant) 0.18 mg micro-insert has been accepted for filing by the U.S. Food and Drug Administration (FDA) and is currently under standard review with a Prescription Drug User Fee Act (PDUFA) date of November 5, 2018. The Company’s pre-clinical development program is focused on using its core Durasert Technology platform to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis and other diseases.
For more information, please visit: http://eyepointpharma.com/